- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04419259
Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea (STOP Ros)
An Open Label Study to Evaluate the Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Nita KF Wienholtz, MD
- Phone Number: 0045-38634612
- Email: nita.wienholtz@regionh.dk
Study Locations
-
-
-
Glostrup, Denmark, Dk-2600
- Recruiting
- Danish Headache Center
-
Contact:
- Nita Wienholtz, MD
-
Sub-Investigator:
- Nita Wienholtz, MD
-
Sub-Investigator:
- Thien Do, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between ages 18 - 65 years who have suffered from rosacea for at least 12 months.
- If patient has concurrent migraine, a daily headache diary must be filled out
Criteria to be met prior to enrollment in the 4-week run-in period:
•Erythematotelangiectatic rosacea with a minimum of 15 days of either:
- PSA > 2, and/or
- Moderate, severe or extreme flushing measured by the Flushing Assessment Tool (FAST)
Exclusion Criteria:
- Systemic treatment for rosacea ended less than five half-lives or 28 days ago, whichever is longest
- Topical treatment for rosacea ended less than five half-lives or 28 days ago, whichever is longest
- Cardiovascular disease of any kind, including cerebrovascular disease
- Hypertension on the experimental day (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
- Hypotension on the experimental day (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
- Ongoing psychiatric disease of any kind - unless it has been effectively treated with a stable treatment for at least 2 months.
- Anamnestic or clinical symptoms of any kind that are deemed relevant for study participation by the physician who examines the patient
- Pregnant or breastfeeding women, or women expecting to conceive during the study
Women of childbearing potential who are unwilling to use an acceptable method of effective contraception during treatment through 16 weeks after the last dose of erenumab. Acceptable methods of effective birth control include not having intercourse (true abstinence, when this is in line with the preferred and usual lifestyle of the subject), hormonal birth control methods (pills, shots/injections, implants, or patches), intrauterine devices, surgical contraceptive methods (vasectomy with medical assessment of the surgical success of this procedure or bilateral tubal ligation), or two barrier methods (each partner must use one barrier method) with spermicide - males must use a condom with spermicide; females must choose either a diaphragm with spermicide, OR cervical cap with spermicide, OR contraceptive sponge with spermicide. Female subjects not of childbearing potential are defined as any female who: is post-menopausal by history, defined as:
- Age ≥ 55 years with cessation of menses for 12 or more months, OR
- Age < 55 years but no spontaneous menses for at least 2 years, OR
- Age < 55 years and spontaneous menses within the past 1 year, but currently amenorrhoeic (e.g. spontaneous or secondary to hysterectomy), AND with postmenopausal gonadotropin levels (luteinizing hormone and follicle-stimulating hormone levels > 40 IU/L) or postmenopausal estradiol levels (< 5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved OR Underwent bilateral oophorectomy OR Underwent hysterectomy OR Underwent bilateral salpingectomy
- Known sensitivity to any component of erenumab
- Previously randomized into an erenumab study
- Member of investigational site staff or relative of the investigator
- Unlikely to be able to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Erenumab
30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
|
30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of erenumab on days of flushing
Time Frame: 12 weeks
|
Mean change in number of days with moderate, severe or extreme flushing from Baseline to week 12. Evaluated by the Flushing Assessment (FAST) Tool part II (moderate, severe or very severe flushing is defined as a score of 4-10 on FAST)
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of erenumab on erythema
Time Frame: 12 weeks
|
Mean change in erythema from Baseline to week 4, 8 and 12. Will be evaluated by Clinicians Erythema Assessment (CEA)
|
12 weeks
|
Effect of erenumab on quality of life: Dermatology Life Quality Index (DLQI)
Time Frame: 12 weeks
|
Mean change in quality of life from Baseline to week 4, 8 and 12. Will be evaluated by Dermatology Life Quality Index (DLQI)
|
12 weeks
|
Proportion of patients that reach a 50% reduction in number of days with flushing
Time Frame: 12 weeks
|
To evaluate the proportion of patients with at least 50% reduction in number of days with moderate, severe or extreme flushing.
Evaluated by the Flushing Assessment (FAST) Tool part II (moderate, severe or very severe flushing is defined as a score of 4-10 on FAST)
|
12 weeks
|
Effect of erenumab on days of flushing
Time Frame: 8 weeks
|
Mean change in number of days with moderate, severe or extreme flushing from Baseline to week 4 and 8. Evaluated by the Flushing Assessment (FAST) Tool part II (moderate, severe or very severe flushing is defined as a score of 4-10 on FAST)
|
8 weeks
|
Effect of erenumab on depression
Time Frame: 12 weeks
|
Mean change in depressive symptoms from Baseline to week 4, 8 and 12. Evaluated by Hospital Anxiety and Depression Scale (HADS).
|
12 weeks
|
Effect of erenumab on overall rosacea symptoms
Time Frame: 12 weeks
|
Proportion of patients with Investigator's Global Assessment (IGA) '0' or '1' with an at least 2-point reduction from baseline to week 4, 8 and 12.
|
12 weeks
|
Effect of erenumab on inflammatory lesions
Time Frame: 12 weeks
|
Mean change in Inflammatory Lesion Count (ILC) from baseline to week 4, 8 and 12
|
12 weeks
|
Proportion of patients that reach a 50% reduction in self-assessed rosacea symptoms
Time Frame: 12 weeks
|
Proportion of patients with at least 50% reduction in number of days with Patient's Self-Assessment (PSA) above 2 from Baseline to week 4, 8 and 12.
|
12 weeks
|
Effect of erenumab on self-assessed rosacea symptoms
Time Frame: 12 weeks
|
Mean change in Patient's Self-Assessment (PSA) above 2 from Baseline to week 4, 8 and 12.
|
12 weeks
|
Effect of erenumab on depressive symptoms
Time Frame: 12 weeks
|
Mean change in Quicky Inventory Depressive Symptomatology (QIDS) from Baseline to week 4, 8 and 12
|
12 weeks
|
Effect of erenumab on overall rosacea severity
Time Frame: 12 weeks
|
Mean change in overall rosacea severity from Baseline to week 4, 8 and 12. Evaluated by Rosacea Area and Severity Index (RASI)
|
12 weeks
|
Effect of erenumab on rosacea symptoms
Time Frame: 12 weeks
|
Mean change in rosacea symptoms from Baseline to week 4, 8 and 12. Evaluated by Rosacea Clinical Scorecard (RCS)
|
12 weeks
|
Effect of erenumab on rosacea-specific quality of life: Rosacea-specific Quality-of-Life index (RosaQoL)
Time Frame: 12 weeks
|
Mean change in rosacea-specific quality of life from Baseline to week 4, 8 and 12. Evaluated by the Rosacea-specific Quality-of-Life index (RosaQoL)
|
12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability of erenumab in patients with rosacea
Time Frame: 12 weeks
|
To evaluate the tolerability of erenumab in patient with rosacea through assessment of adverse events at every visit from Baseline to week 4, 8 and 12.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Messoud Ashina, Professor, Danish Headache Center
- Study Director: Nita KF Wienholtz, MD, Danish Headache Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ROS031019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
Clinical Trials on AMG 334
-
Solvay PharmaceuticalsCompletedPharmacology, ClinicalNetherlands
-
Danish Headache CenterNovartis; AmgenCompletedPost-Concussion Syndrome | Mild Traumatic Brain Injury | Post-Traumatic HeadacheDenmark
-
AmgenCompleted
-
AmgenCompleted
-
Charite University, Berlin, GermanyCompletedHeadache Disorders, Primary | Cluster Headache | Trigeminal Autonomic Cephalalgias | Brain DiseaseGermany
-
AmgenCompletedMigraineUnited States
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AmgenCompletedMigraineUnited States, Denmark, France, Spain, Portugal, Russian Federation, Greece, Switzerland
-
AmgenCompleted